BPC-157 human trial initiation
PMID: 96 ChoiYChoiSIKimNNamRHJangJYNaHYet al
Use within 3045 days under standard laboratory conditions
(ii) For agreement periods beginning on or after January 1, 2027, if the ACO has fewer than 5,000 assigned beneficiaries in benchmark year (BY) 1, BY2 or BY3, in conducting financial reconciliation for each performance year, CMS determines whether to apply an alternative performance payment limit, rather than the performance payment limit specified in paragraph (d)(1)(i)(B)( 2 ), (d)(1)(ii)(B)( 2 ), (d)(1)(iii)(B)( 2 ), (d)(1)(iv)(B)( 2 ), and (d)(1)(v)(B)( 2 ) of this section, as applicable, as follows: (A) CMS calculates the value for total benchmark expenditures as the product of an ACO's per capita updated benchmark expenditures for the performance year and an ACO's assigned beneficiary person years for the benchmark year with the lowest number of assigned beneficiaries
However, the absence of known interactions may partly reflect the limited scope of formal studies on NAD+ therapy, so this lack of interactions should be interpreted with caution
